JPWO2022081925A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022081925A5
JPWO2022081925A5 JP2023523007A JP2023523007A JPWO2022081925A5 JP WO2022081925 A5 JPWO2022081925 A5 JP WO2022081925A5 JP 2023523007 A JP2023523007 A JP 2023523007A JP 2023523007 A JP2023523007 A JP 2023523007A JP WO2022081925 A5 JPWO2022081925 A5 JP WO2022081925A5
Authority
JP
Japan
Prior art keywords
compound according
disorder
hydrogen
item
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545508A (ja
JP2023545508A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/055102 external-priority patent/WO2022081925A1/en
Publication of JP2023545508A publication Critical patent/JP2023545508A/ja
Publication of JPWO2022081925A5 publication Critical patent/JPWO2022081925A5/ja
Publication of JP2023545508A5 publication Critical patent/JP2023545508A5/ja
Pending legal-status Critical Current

Links

JP2023523007A 2020-10-14 2021-10-14 Ikzf2又はikzf4を分解する三環式リガンド Pending JP2023545508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091875P 2020-10-14 2020-10-14
US63/091,875 2020-10-14
PCT/US2021/055102 WO2022081925A1 (en) 2020-10-14 2021-10-14 Tricyclic ligands for degradation of ikzf2 or ikzf4

Publications (3)

Publication Number Publication Date
JP2023545508A JP2023545508A (ja) 2023-10-30
JPWO2022081925A5 true JPWO2022081925A5 (https=) 2024-10-22
JP2023545508A5 JP2023545508A5 (https=) 2024-10-22

Family

ID=81208646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523007A Pending JP2023545508A (ja) 2020-10-14 2021-10-14 Ikzf2又はikzf4を分解する三環式リガンド

Country Status (10)

Country Link
US (1) US20230339902A1 (https=)
EP (1) EP4228639A4 (https=)
JP (1) JP2023545508A (https=)
KR (1) KR20230107569A (https=)
CN (1) CN116783180A (https=)
AU (1) AU2021361043A1 (https=)
CA (1) CA3194169A1 (https=)
IL (1) IL302038A (https=)
MX (1) MX2023004374A (https=)
WO (1) WO2022081925A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN116457339A (zh) * 2020-10-14 2023-07-18 C4医药公司 用于医学治疗的降解新底物的三环化合物
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN118201923A (zh) * 2021-10-15 2024-06-14 海南先声再明医药股份有限公司 三环类化合物
EP4540241A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Substituted piperidines as ck1a degraders
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN116655595A (zh) * 2023-06-05 2023-08-29 中国人民解放军军事科学院军事医学研究院 2,6-哌啶二酮衍生物及其制备和用途
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025006783A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras
WO2025097092A1 (en) * 2023-11-02 2025-05-08 Neomorph, Inc. Substituted 3-(5-(4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and 3-(2-(4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6h-pyrrolo[3,4-b]pyridin-6-yl)piperidine-2,6-dione derivatives and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025162410A1 (zh) * 2024-01-31 2025-08-07 微境生物医药科技(上海)有限公司 新型蛋白降解剂及抗体-蛋白降解剂偶联物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6504034B2 (en) * 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
CN105985282B (zh) * 2015-01-28 2020-12-08 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US11220515B2 (en) * 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
EP3813834B1 (en) * 2018-06-29 2025-03-26 Dana-Farber Cancer Institute, Inc. New crbn modulators
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
DK3820573T3 (da) * 2018-07-10 2023-10-23 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
KR20210106437A (ko) * 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
EP3924055B1 (en) * 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) * 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN120172958A (zh) * 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
WO2020243379A1 (en) * 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
US20240383886A1 (en) * 2019-12-20 2024-11-21 Calico Life Sciences Llc Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
TW202140441A (zh) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
MX2023001545A (es) * 2020-08-07 2023-05-03 C4 Therapeutics Inc Terapias ventajosas para trastornos mediados por ikaros o aiolos.
CN116457339A (zh) * 2020-10-14 2023-07-18 C4医药公司 用于医学治疗的降解新底物的三环化合物
EP4228625A4 (en) * 2020-10-14 2026-01-14 C4 Therapeutics Inc TRICYCLIC HETEROBFUNCTIONAL COMPOUNDS FOR TARGETED PROTEIN DEGRADATION

Similar Documents

Publication Publication Date Title
JPWO2022081925A5 (https=)
JP2020007311A5 (https=)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP7020218B2 (ja) Ep4拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ
JP2005534669A5 (https=)
AU2023201399A1 (en) Modulators of the integrated stress pathway
JP2025024130A5 (https=)
JP2010538094A5 (https=)
CN115605479A (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2020512387A5 (https=)
JPWO2019191112A5 (https=)
JP2025163128A5 (https=)
EA020885B1 (ru) Ингибиторы протеинкиназы и их применение
JP5695200B2 (ja) 複素環アミノベルバミン誘導体、その調製方法及び使用
JP2018513832A5 (https=)
JPWO2021127561A5 (https=)
JP2024533563A (ja) アザインダゾール大環化合物及びその使用
JPWO2022081927A5 (https=)
JP6606806B2 (ja) 重水素化キナゾリノン化合物及び該化合物を含む薬物組成物
KR20230074722A (ko) 피라졸 보론산 화합물, 이를 함유하는 약학적 조성물, 및 이의 용도
CN113024422A (zh) 丁苯酞开环化合物、药物化合物以及它们的制备方法、组合物和应用
JP2002503674A5 (https=)
WO2002030872A1 (en) Novel aliphatic compounds, process for their preparation and their usage
JP2009537503A (ja) ルテニウム(ii)化合物
JP2006528947A5 (https=)